NIKKEI 225
39,595.21 +253.67 (+0.64%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
82.02 +0.28 (+0.34%) GOLD FUTURES
2,337.90 +1.30 (+0.06%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,715.62 +618.38 (+1.29%)
REGN Jun 2024 1020.000 put
| Previous close | 2.1300 |
| Open | 0.5300 |
| Bid | 0.0000 |
| Ask | 4.7000 |
| Strike | 1,020.00 |
| Expiry date | 2024-06-28 |
| Day's range | 0.5300 - 0.5300 |
| Contract range | N/A |
| Volume | |
| Open interest | 19 |
GlobeNewswireRegeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s webs
- GlobeNewswire
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
